| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | SELSYM BIOTECH INC | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41DK135288 | SymHeal: A novel therapy for treating non-healing diabetic ulcers | 000 | 1 | NIH | 12/26/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | SELSYM BIOTECH INC | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL162242 | Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design | 000 | 1 | NIH | 4/17/2024 | $0 |
| | 2024 | 2021 | SELSYM BIOTECH INC | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL156763 | Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma | 000 | 1 | NIH | 1/19/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | SELSYM BIOTECH, INC. | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL156763 | Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma | 000 | 1 | NIH | 10/31/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $487,975 ) |
| | 2022 | 2022 | SELSYM BIOTECH, INC. | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL162242 | Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design | 001 | 1 | NIH | 9/24/2022 | $0 |
| | 2022 | 2022 | SELSYM BIOTECH, INC. | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL162242 | Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design | 000 | 1 | NIH | 3/5/2022 | $258,501 |
| | 2022 | 2022 | SELSYM BIOTECH, INC. | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41DK135288 | SymHeal: A novel therapy for treating non-healing diabetic ulcers | 000 | 1 | NIH | 9/19/2022 | $229,474 |
|
| Issue Date FY: 2021 ( Subtotal = $254,878 ) |
| | 2021 | 2021 | SELSYM BIOTECH, INC. | 101 LINECREST CT | CARY | NC | 27518-2481 | WAKE | USA | R41HL156763 | Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma | 000 | 1 | NIH | 5/21/2021 | $254,878 |
|
|
